Cancer patients get continued access to experimental drug in Long-Term study
NCT ID NCT05061823
First seen Feb 02, 2026 · Last updated May 21, 2026 · Updated 11 times
Summary
This study gave 22 cancer patients ongoing access to the drug bintrafusp alfa after they completed earlier trials. Researchers tracked side effects and survival for up to 5 years to understand the drug's long-term safety and effectiveness. The goal was to keep treating patients while gathering important data.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Adana City Hospital - Parent Account
Adana, Turkey (Türkiye)
-
Asan Medical Center
Seoul, South Korea
-
BHI of Omsk region "Clinical Oncology Dispensary" - PARENT
Omsk, Russia
-
Centre Hospitalier de l'Ardenne - PARENT
Libramont, Belgium
-
Chang Gung Memorial Hospital,Linkou
Taoyuan County, Taiwan
-
Communal Enterprise Volyn Regional Medical Center of Oncology of Volyn Regional Council - Department of Oncochemotherapy
Lutsk, Ukraine
-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Oncologia Medica
Lazio, Italy
-
Gachon University Gil Medical Center
Incheon, South Korea
-
Harbin Medical University Cancer Hospital
Harbin, China
-
Hospital Clinico Universitario de Valencia - Servicio de Hematologia y Oncologia Medica
Valencia, Spain
-
Hospital General Universitario Gregorio Marañón
Madrid, Spain
-
Hospital Universitario Ramon y Cajal - Servicio de Oncologia
Madrid, Spain
-
NIH National Institutes of Health/GMB LTIB
Bethesda, Maryland, 20892, United States
-
National Cancer Center Hospital
Chūōku, Japan
-
National Cancer Center Hospital East
Kashiwa-shi, Japan
-
Saitama Medical University International Medical Center
Hidaka-shi, Japan
-
Seoul National University Hospital
Seoul, South Korea
-
Severance Hospital, Yonsei University Health System
Seoul, South Korea
-
Taichung Veterans General Hospital
Taichung, Taiwan
-
The Center for Cancer and Blood Disorders a Division of American Oncology Partners of Maryland, P.A.
Bethesda, Maryland, 20817, United States
-
Universitaetsklinikum Carl Gustav Carus TU Dresden - Medizinische Klinik I
Dresden, Germany
Conditions
Explore the condition pages connected to this study.